PADRE peptide-MHC Class II complex (PADRE-MHC II complex)

The PADRE peptide-MHC Class II complex consists of a synthetic peptide called PADRE (Pan DR-binding epitope, commonly sequence AKFVAAWTLKAAA), engineered for high-affinity binding to the majority of human HLA-DR Class II MHC molecules. PADRE’s interaction with MHC II forms a peptide-MHC complex that is recognized by CD4+ T-cells, triggering robust helper T-cell responses. This universality makes the complex highly valuable as a vaccine adjuvant and research tool for immunotherapy, as it overcomes the variability of peptide presentation caused by MHC polymorphism. The complex is used in several experimental and clinical vaccines against infectious diseases, cancer, and neurodegenerative diseases, owing to its ability to enhance immune recognition across diverse genetic backgrounds[7][5][6][8].

Other names

Pan DR-binding epitope-MHC II complexPan-DR peptide-MHC II complexPADRE-MHC II complex

The PADRE peptide binds broadly to HLA-DR receptors (Class II MHC), forming a stable complex that efficiently recruits and activates CD4+ T-cells regardless of the individual's MHC allele. This enhances immune responses to linked antigens, making the PADRE-MHC II complex a universal epitope for helping vaccines stimulate robust helper T-cell activity[7][6][8].